6,874 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Heartland Bank & Trust Co

Heartland Bank & Trust Co bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 6,874 shares of the biopharmaceutical company’s stock, valued at approximately $770,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Annis Gardner Whiting Capital Advisors LLC raised its holdings in shares of Gilead Sciences by 158.8% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 216 shares during the last quarter. Whipplewood Advisors LLC purchased a new stake in Gilead Sciences in the 4th quarter valued at about $35,000. Synergy Investment Management LLC purchased a new stake in Gilead Sciences in the 4th quarter valued at about $40,000. Lee Danner & Bass Inc. purchased a new stake in Gilead Sciences in the 4th quarter valued at about $41,000. Finally, Investment Research & Advisory Group Inc. increased its stake in Gilead Sciences by 33.3% in the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 100 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider now directly owns 121,152 shares of the company’s stock, valued at approximately $13,026,263.04. The trade was a 18.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the sale, the chief financial officer now directly owns 168,174 shares of the company’s stock, valued at $17,893,713.60. This represents a 1.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 48,500 shares of company stock valued at $5,236,245 in the last three months. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 0.5%

Shares of NASDAQ:GILD opened at $108.50 on Friday. The firm has a fifty day moving average price of $106.16 and a two-hundred day moving average price of $102.81. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. Gilead Sciences, Inc. has a one year low of $66.01 and a one year high of $119.96. The company has a market cap of $134.97 billion, a price-to-earnings ratio of 22.84, a PEG ratio of 0.70 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period last year, the firm earned ($1.32) EPS. The business’s quarterly revenue was down .3% compared to the same quarter last year. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.91%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences’s payout ratio is 66.53%.

Analyst Ratings Changes

Several research firms have commented on GILD. Wells Fargo & Company increased their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Morgan Stanley increased their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a research note on Thursday, March 27th. Finally, Bank of America raised their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.